112 related articles for article (PubMed ID: 23083604)
1. MR-spectroscopy at 1.5 tesla and 3 tesla. Useful? A systematic review and meta-analysis.
Baltzer PA; Dietzel M; Kaiser WA
Eur J Radiol; 2012 Sep; 81 Suppl 1():S6-9. PubMed ID: 23083604
[No Abstract] [Full Text] [Related]
2. L-COSY of breast cancer at 3T.
Ramadan S; Baltzer PA; Lin A; Stanwell P; Box H; Kaiser WA; Mountford CE
Eur J Radiol; 2012 Sep; 81 Suppl 1():S129-31. PubMed ID: 23083559
[No Abstract] [Full Text] [Related]
3. MR spectroscopy in the breast clinic is improving.
Mountford CE; Schuster C; Baltzer PA; Malycha P; Kaiser WA
Eur J Radiol; 2012 Sep; 81 Suppl 1():S104-6. PubMed ID: 23083547
[No Abstract] [Full Text] [Related]
4. What is new in breast MRI spectroscopy.
Nelson MT; Bolan PJ; Garwood M; Everson L; Emory T; Kuehn-Hajder J
Eur J Radiol; 2012 Sep; 81 Suppl 1():S107-8. PubMed ID: 23083548
[No Abstract] [Full Text] [Related]
5. Quantitative multivoxel proton chemical shift imaging of the breast.
Sijens PE; Dorrius MD; Kappert P; Baron P; Pijnappel RM; Oudkerk M
Magn Reson Imaging; 2010 Apr; 28(3):314-9. PubMed ID: 20071119
[TBL] [Abstract][Full Text] [Related]
6. CEST-imaging: A new contrast in MR-mammography by means of chemical exchange saturation transfer.
Schmitt B; Trattnig S; Schlemmer HP
Eur J Radiol; 2012 Sep; 81 Suppl 1():S144-6. PubMed ID: 23083567
[No Abstract] [Full Text] [Related]
7. Choline as a biomarker for cell proliferation: do the results from proton MR spectroscopy show difference between HER2/neu positive and negative breast cancers?
Baek HM; Chen JH; Nalcioglu O; Su MY
Int J Cancer; 2008 Sep; 123(5):1219-21. PubMed ID: 18546272
[No Abstract] [Full Text] [Related]
8. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
[TBL] [Abstract][Full Text] [Related]
9. In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy.
Russo F; Mazzetti S; Grignani G; De Rosa G; Aglietta M; Anselmetti GC; Stasi M; Regge D
Eur Radiol; 2012 May; 22(5):1131-9. PubMed ID: 22138734
[TBL] [Abstract][Full Text] [Related]
10. Malignant transformation: the role of MRS.
Jiang L; Wijnen JP; Glunde K
Eur J Radiol; 2012 Sep; 81 Suppl 1():S66-8. PubMed ID: 23083608
[No Abstract] [Full Text] [Related]
11. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
Bolan PJ; Kim E; Herman BA; Newstead GM; Rosen MA; Schnall MD; Pisano ED; Weatherall PT; Morris EA; Lehman CD; Garwood M; Nelson MT; Yee D; Polin SM; Esserman LJ; Gatsonis CA; Metzger GJ; Newitt DC; Partridge SC; Hylton NM;
J Magn Reson Imaging; 2017 Jul; 46(1):290-302. PubMed ID: 27981651
[TBL] [Abstract][Full Text] [Related]
12. Hyperpolarized C-13 studies of cancer metabolism in animal models. Hype or real?
Lenkinski RE
Eur J Radiol; 2012 Sep; 81 Suppl 1():S85-6. PubMed ID: 23083616
[No Abstract] [Full Text] [Related]
13. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters.
Sitter B; Lundgren S; Bathen TF; Halgunset J; Fjosne HE; Gribbestad IS
NMR Biomed; 2006 Feb; 19(1):30-40. PubMed ID: 16229059
[TBL] [Abstract][Full Text] [Related]
14. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast.
Lenkinski RE; Wang X; Elian M; Goldberg SN
Magn Reson Med; 2009 Jun; 61(6):1286-92. PubMed ID: 19365855
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance spectroscopy of the breast: current status.
Bolan PJ
Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):625-39. PubMed ID: 23928249
[TBL] [Abstract][Full Text] [Related]
16. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors.
Tozaki M; Hoshi K
AJR Am J Roentgenol; 2010 May; 194(5):1384-90. PubMed ID: 20410429
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of treatment response after chemoradiotherapy for head and neck cancer using in vivo 1H MR spectroscopy.
King AD; Yeung DK; Yu KH; Mo FK; Hu CW; Bhatia KS; Tse GM; Vlantis AC; Wong JK; Ahuja AT
Eur Radiol; 2010 Jan; 20(1):165-72. PubMed ID: 19652977
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of hemangioblastomas from pilocytic astrocytomas using 3-T magnetic resonance perfusion-weighted imaging and MR spectroscopy.
She DJ; Xing Z; Zeng Z; Shang XY; Cao DR
Neuroradiology; 2015 Mar; 57(3):275-81. PubMed ID: 25487356
[TBL] [Abstract][Full Text] [Related]
19. Multimodal assessment of early tumor response to chemotherapy: comparison between diffusion-weighted MRI, 1H-MR spectroscopy of choline and USPIO particles targeted at cell death.
Radermacher KA; Magat J; Bouzin C; Laurent S; Dresselaers T; Himmelreich U; Boutry S; Mahieu I; Vander Elst L; Feron O; Muller RN; Jordan BF; Gallez B
NMR Biomed; 2012 Apr; 25(4):514-22. PubMed ID: 21874657
[TBL] [Abstract][Full Text] [Related]
20. 1H NMR analysis of choline metabolites in fine-needle-aspirate biopsies of breast cancer.
Pearce JM; Mahoney MC; Lee JH; Chu WJ; Cecil KM; Strakowski SM; Komoroski RA
MAGMA; 2013 Jun; 26(3):337-43. PubMed ID: 23053715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
